Emicizumab injection (DrugBank: Emicizumab)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
288 | Autoimmune acquired coagulation factor deficiency [Autoimmune Hemorrhaphilia XIII (~Mar 2017)] | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04188639 (ClinicalTrials.gov) | May 2020 | 4/12/2019 | Emicizumab in Acquired Hemophilia A | Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial | Hemophilia A, Acquired | Drug: Emicizumab Injection | GWT-TUD GmbH | Hoffmann-La Roche;Hannover Medical School | Not yet recruiting | 18 Years | N/A | All | 51 | Phase 2 | NULL |